In ROTY's model account today, I added to 2 positions and initiated one new pilot purchase (trades occur at day's closing price for the sake of transparency, so members often get in at better cost average).
We added to an ASH (December) play as thesis strengthened.
We added to a platform tech idea where I am willing to hold into 2020 given promising data generated across all assets.
We initiated a pilot position in a compelling gene therapy platform play, as valuation got too cheap to ignore.
Before these trades, cash position for our model account was at 40%. As other catalysts occur, I hope to continue raising cash where merited and stay conservative.
On the other hand, I can't ignore compelling setups (especially those with near term catalysts or where valuation is quite cheap relative to current & future prospects).
My suggestion to investors is to stay prudent, hunkering down into conviction ideas while cutting loose those that no longer make sense to own in this climate. In response to many private messages where readers are concerned about risk levels, I continue to state that excess worry is a sign you need to either sell or size down (raising enough cash to sleep well at night).
I look forward on your thoughts on what names you are scooping up going into Q4 2019. With current market volatility, I believe it's best to focus on near term catalysts or ideas where you are willing to hold through volatility with multi-year time frame.
For readers who wish to take their biotech investing/trading efforts to the next level, I invite you to try out the 2 Week Free Trial in ROTY (Runners of the Year).
ROTY is a tight knit 500+ member community of experienced biotech investors, profitable traders, industry veterans and novices. Our active Live Chat is characterized by generous sharing of due diligence, knowledge and continuous improvement.
Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account